Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta‐analysis of randomized placebo‐controlled trials
Abstract
Objective: The aim of this research was to perform a systematic review to identify all randomized controlled trials (RCTs) evaluating the efficacy and safety of add‐on celecoxib for treatment of depressive mood episodes. Methods: Four electronic databases were systematically searched from their inception to 8 August 2013: PubMed, Cochrane Library (Cochrane Central Register of Controlled Trials), Scopus, and PsychINFO. Pooled difference in means of Hamilton Depression Rating Scale score, pooled odds ratio (OR) of treatment response, and pooled OR of remission were calculated as the main effect size. A random‐effects model was used to pool the data across studies. Results: Five RCTs (four unipolar depression studies and one bipolar depression study) were included in the systematic review for qualitative data synthesis. Moreover, quantitative results of four RCTs (unipolar depression studies) were meta‐analyzed. The add‐on celecoxib group had a statistically significant decrease in means of the Hamilton Depression Rating Scale score at week 4 (pooled difference in means = 3.3, 95%CI [1.2–5.3],p = 0.002) and week 6 (pooled difference in means = 3.43, 95%CI [1.9–4.9],p < 0.0001). The add‐on celecoxib group also showed higher response (pooled OR = 6.6, 95%CI [2.5–17],p < 0.0001) and remission rates (pooled OR = 6.6, 95%CI [2.7–15.9],p < 0.0001) compared with the placebo group. Conclusions: Celecoxib can be considered as an effective add‐on treatment for unipolar depressive patients. Making conclusion regarding the efficacy and safety for longer duration warrants further studies with a larger sample size and longer follow‐up duration. Copyright © 2014 John Wiley & Sons, Ltd.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Celecoxib might help as an adjunct treatment for unipolar depression.
“Celecoxib, a selective inhibitor of the cyclooxygenase 2 enzyme, may be effective as an add-on treatment for unipolar depression (295).”
From A brain-centric model of suicidal behavior (2020) · cites this paper as [295]
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722 · see citing works
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · see citing works
Duval, S., & Tweedie, R. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00455.x · Cited by 14,099 · see citing works
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729 · see citing works
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848 · see citing works
Is there an epidemic of child or adolescent depression?
Jane Costello, E., Erkanli, A., & Angold, A. (2006) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2006.01682.x · Cited by 983 · cited 1× · see citing works
“Depression is one of the most common psychiatric disorders in all regions of the world (Costello et al., 2006).”
BackgroundMüller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001805 · Cited by 794 · see citing works
Elevated inflammation levels in depressed adults with a history of childhood maltreatment
Danese, A., Moffitt, T. E., Pariante, C. M., Ambler, A., Poulton, R., & Caspi, A. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.4.409 · Cited by 641 · see citing works
Nelson, J. C., & Papakostas, G. I. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030312 · Cited by 552 · see citing works
Cytokines as mediators of depression: what can we learn from animal studies?
Dunn, A. J., Swiergiel, A. H., & Beaurepaire, R. D. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.023 · Cited by 459 · see citing works
Akhondzadeh, S., Jafari, S., Raisi, F., Nasehi, A. A., Ghoreishi, A., Salehi, B., Mohebbi-Rasa, S., Raznahan, M., & Kamalipour, A. (2009) · Depression and Anxiety · doi:10.1002/da.20589 · Cited by 397 · see citing works
Müller, N., Riedel, M. J., Scheppach, C., Brandstätter, B., Sokullu, S., Krampe, K., Ulmschneider, M., Engel, R. R., Möller, H., & Schwarz, M. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1029 · Cited by 388 · see citing works
Abbasi, S.-H., Hosseini, F., Modabbernia, A., Ashrafi, M., & Akhondzadeh, S. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.03.033 · Cited by 344 · see citing works
Nery, F. G., Monkul, E. S., Hatch, J. P., Fonseca, M., Zunta‐Soares, G. B., Frey, B. N., Bowden, C. L., & Soares, J. C. (2008) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.912 · Cited by 298 · see citing works
Akhondzadeh, S., Tabatabaee, M., AMINI, H., Ahmadi-Abhari, S.-A., ABBASI, S., & BEHNAM, B. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2006.11.016 · Cited by 290 · see citing works
Inflammation, Glutamate, and Glia in Depression:<i>A Literature Review</i>
McNally, L., Bhagwagar, Z., & Hannestad, J. (2008) · CNS Spectrums · doi:10.1017/s1092852900016734 · Cited by 289 · see citing works
The role of the innate immune system in psychiatric disorders
Jones, K. A., & Thomsen, C. (2013) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.10.002 · Cited by 274 · see citing works
Müller, N., Krause, D., Dehning, S., Musil, R., Schennach-Wolff, R., Obermeier, M., Möller, H., Klauß, V., Schwarz, M., & Riedel, M. J. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.04.015 · Cited by 251 · see citing works
Papakostas, G. I., Shelton, R. C., Smith, J., & D, M. F. M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0602 · Cited by 242 · see citing works
Song, C., Lin, A., Bonaccorso, S., Heide, C., Verkerk, R., Kenis, G., Bosmans, E., Scharpe, S., Whelan, A., Cosyns, P., et al. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00025-1 · Cited by 232 · see citing works
Inflammatory markers in depression
Dinan, T. G. (2008) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328315a561 · Cited by 206 · see citing works
Depression, immunocompetence, and prostaglandins of the E series
Calabrese, J. R., Skwerer, R. G., Barna, B. P., Gulledge, A. D., Valenzuela, R., Butkus, A., Subichin, S., & Krupp, N. E. (1986) · Psychiatry Research · doi:10.1016/0165-1781(86)90040-5 · Cited by 205 · see citing works
Mood disorders and complementary and alternative medicine: a literature review
Qureshi, N. A., & Al-Bedah (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s43419 · Cited by 155 · see citing works
CSF Prostaglandin Levels in Depressed and Schizophrenic Patients
Linnoila, M. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790040059008 · Cited by 151 · see citing works
Guo, J.-Y., Li, C.-Y., Ruan, Y.-P., Sun, M., Qi, X.-L., Zhao, B.-S., & Luo, F. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.03.076 · Cited by 148 · see citing works
Khoraminya, N., Tehrani‐Doost, M., Jazayeri, S., Hosseini, A. F., & Djazayery, A. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412465022 · Cited by 145 · see citing works
Increased level of salivary prostaglandins in patients with major depression
Ohishi, K., Ueno, R., Nishino, S., Sakai, T., & Hayaishi, O. (1988) · Biological Psychiatry · doi:10.1016/0006-3223(88)90283-1 · Cited by 138 · see citing works
Martinez, J. M., Garakani, A., Yehuda, R., & Gorman, J. M. (2012) · Depression and Anxiety · doi:10.1002/da.20876 · Cited by 131 · see citing works
Inflammatory Biomarkers and Depression
Müller, N., Myint, A.-M., & Schwarz, M. (2010) · Neurotoxicity Research · doi:10.1007/s12640-010-9210-2 · Cited by 125 · see citing works
COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence.
Müller, N. (2010) · PubMed · Cited by 122 · see citing works
Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?
McNamara, R. K., & Lotrich, F. E. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.98 · Cited by 109 · see citing works
NSAIDs Are Associated with Lower Depression Scores in Patients with Osteoarthritis
Iyengar, R. L., Gandhi, S., Aneja, A., Thorpe, K. E., Razzouk, L., Greenberg, J., Mosovich, S., & Farkouh, M. E. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.02.037 · Cited by 106 · see citing works
Salivary prostaglandin concentrations: possible state indicators for major depression
Nishino, S., Ueno, R., Ohishi, K., Sakai, T., & Hayaishi, O. (1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.3.365 · Cited by 88 · see citing works
Wright, B. M., Eiland, E. H., & Lorenz, R. A. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1204 · Cited by 84 · see citing works
Review of the cardiovascular safety of COXIBs compared to NSAIDS.
Moodley, I. (2008) · Europe PMC (PubMed Central) · Cited by 56 · see citing works
Towards achieving remission in the treatment of depression
Mendlewicz, J. (2008) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2008.10.4/jmendlewicz · Cited by 52 · see citing works
Collantes‐Estévez, E., & Fernández, C. (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125001938 · Cited by 52 · see citing works
Hantouche, E. G., Akiskal, H. S., Lancrenon, S., & Châtenet-Duchêne, L. (2004) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.01.006 · Cited by 42 · see citing works
Metyrapone in treatment-resistant depression
Sigalas, P. D., Garg, H., Watson, S., McAllister-Williams, H., & Ferrier, I. N. (2012) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312436597 · Cited by 40 · see citing works
Chronic Administration of Lamotrigine Downregulates COX-2 mRNA and Protein in Rat Frontal Cortex
Lee, H., Ertley, R. N., Rapoport, S. I., Bazinet, R. P., & Rao, J. S. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9526-3 · Cited by 38 · see citing works
Mtabaji, J., Manku, M. S., & Horrobin, D. F. (1977) · Prostaglandins · doi:10.1016/0090-6980(77)90161-7 · Cited by 38 · see citing works
Mattey, D. L., HASSELL, A. B., Dawes, P. T., Ollier, W., & Hajeer, A. H. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199912)42:12 · Cited by 38 · see citing works
Treating Depression to Full Remission
Trivedi, M. H. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.8017br6c.e01 · Cited by 27 · see citing works
Maintenance therapy of celecoxib for major depression with mimicking neuropsychological dysfunction
Chen, C., Tzeng, N., & Chen, Y.-C. (2010) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2010.07.001 · Cited by 25 · see citing works
Cardiovascular effects of common analgesics.
Ong, H. T., Ong, L. M., Tan, T., & Chean, K. Y. (2013) · PubMed · Cited by 23 · see citing works
Current perspective on the cardiovascular effects of coxibs.
Konstam, M. A., & Weir, M. R. (2002) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.69.suppl_1.si47 · Cited by 22 · see citing works
Efficacy of vitamin D supplementation in depression in adults: a systematic review protocol
Li, G., Mbuagbaw, L. C. E., Samaan, Z., Zhang, S., Adachi, J. D., Παπαϊωάννου, Α., & Thabane, L. (2013) · Systematic Reviews · doi:10.1186/2046-4053-2-64 · Cited by 21 · see citing works
Jon, D., Kim, D. H., Seo, H., Kwon, Y., Kim, M.-D., Yang, J.-C., Suh, H.-S., Min, K. J., Pae, C., & Bahk, W. (2013) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3182a31f3d · Cited by 17 · see citing works
A review of the psychoneuroimmunologic concepts on the etiology of depressive disorders.
Vidrih, B., Karlović, D., Pašić, M. B., Uremović, M., Mufić, A. K., & Matošić, A. (2012) · PubMed · Cited by 11 · see citing works
Schatzberg, A. (2008) · CNS Spectrums · doi:10.1017/s1092852900002911 · Cited by 4 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
<p>Management of Treatment-Resistant Depression: Challenges and Strategies</p>
Voineskos, D., Daskalakis, Z. J., & Blumberger, D. M. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s198774 · Cited by 446 · see citing works
Kynurenine pathway in depression: a systematic review and meta-analysis
Ogyu, K., Kubo, K., Noda, Y., Iwata, Y., Tsugawa, S., Omura, Y., Wada, M., Tarumi, R., Plitman, E., Moriguchi, S., et al. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.03.023 · Cited by 301 · see citing works
Kopschina Feltes, P., Doorduin, J., Klein, H. C., Juárez-Orozco, L. E., Dierckx, R. A., Moriguchi-Jeckel, C. M., & de Vries, E. F. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117711708 · Cited by 279 · see citing works
Role of Inflammation in Suicide: From Mechanisms to Treatment
Brundin, L., Bryleva, E. Y., & Thirtamara Rajamani, K. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.116 · Cited by 257 · see citing works
“Several recent meta-analyses of randomized controlled trials (RCTs) have found a COX-2 inhibitor celecoxib to be an effective add-on treatment for unipolar depression as celecoxib decreases depression severity and increases remission rates (Faridhosseini et al , 2014; Na et al , 2014).”
A brain-centric model of suicidal behavior
Mann, J. J., & Rizk, M. M. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081224 · Cited by 214 · see citing works
Therapeutic Implications of Brain–Immune Interactions: Treatment in Translation
Miller, A. H., Haroon, E., & Felger, J. C. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.167 · Cited by 152 · see citing works
Anti-inflammatory treatments for mood disorders: Systematic review and meta-analysis
Husain, M. I., Strawbridge, R., Stokes, P. R., & Young, A. H. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725711 · Cited by 139 · see citing works
van der Feltz‐Cornelis, C., Allen, S. F., Holt, R. I. G., Roberts, R., Nouwen, A., & Sartorius, N. (2021) · Brain and Behavior · doi:10.1002/brb3.1981 · Cited by 130 · see citing works
The role of neuroinflammation on pathogenesis of affective disorders
Rhie, S. J., Jung, E.-Y., & Shim, I. (2020) · Journal of Exercise Rehabilitation · doi:10.12965/jer.2040016.008 · Cited by 126 · see citing works
Liu, J., Buisman-Pijlman, F., & Hutchinson, M. R. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00309 · Cited by 119 · see citing works
Inflammation as a treatment target in mood disorders: review
Jones, B. D. M., Daskalakis, Z. J., Carvalho, A. F., Strawbridge, R., Young, A. H., Mulsant, B. H., & Husain, M. I. (2020) · BJPsych Open · doi:10.1192/bjo.2020.43 · Cited by 106 · see citing works
Cognitive Dysfunction in Depression – Pathophysiology and Novel Targets
Carvalho, A., Miskowiak, K., Hyphantis, T., Kohler, C., Alves, G., Bortolato, B., G. Sales, P., Machado-Vieira, R., Berk, M., & McIntyre, R. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141130203627 · Cited by 107 · see citing works
Özyurt, G., & Binici, N. C. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.08.007 · Cited by 74 · see citing works
Baune, B. T., Sampson, E., Louise, J., Hori, H., Schubert, K. O., Clark, S. R., Mills, N. T., & Fourrier, C. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.07.092 · Cited by 62 · see citing works
Cyclooxygenase-2 inhibition reduces stress-induced affective pathology
Gamble-George, J. C., Baldi, R., Halladay, L., Kocharian, A., Hartley, N., Silva, C. G., Roberts, H., Haymer, A., Marnett, L. J., Holmes, A., et al. (2016) · eLife · doi:10.7554/elife.14137 · Cited by 55 · see citing works
Interleukin-4 Is a Participant in the Regulation of Depressive-like Behavior
Wachholz, S., Knorr, A., Mengert, L., Plümper, J., Sommer, R., Juckel, G., & Friebe, A. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.03.020 · Cited by 45 · see citing works
Martynhak, B. J., Hogben, A. L., Zanos, P., Georgiou, P., Andreatini, R., Kitchen, I., Archer, S. N., von Schantz, M., Bailey, A., & van der Veen, D. R. (2017) · Scientific Reports · doi:10.1038/srep40399 · Cited by 23 · see citing works
- Authors
- Faridhosseini, F., Sadeghi, R., Farid, L., & Pourgholami, M.
- Affiliations
- Psychiatry and Behavioral Sciences Research Center Mashhad University of Medical Sciences Iran
- Mashhad University of Medical Sciences (IR)
- Corresponding author
- Pourgholami, Meysam
- ORCID
- Sadeghi, Ramin
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 2014-03-16
- Volume
- 29
- Issue
- 3
- Pages
- 216-223
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W1521143345
- Cited by
- 89
- References
- 50
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 3 · 2023: 12 · 2022: 4 · 2021: 4 · 2020: 11 · 2019: 7 · 2018: 8 · 2017: 9 · 2016: 9 · 2015: 14
- FWCI
- 1.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Human Psychopharmacology Clinical and Experimental (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- celecoxib, adjunctive therapy, major depressive disorder, bipolar depression, antidepressant efficacy, remission, treatment response, nonsteroidal anti-inflammatory drugs, drug safety
- MeSH terms
- Celecoxib, Antidepressive Agents, Bipolar Disorder, Major Depressive Disorder, Depressive Disorder, Drug Therapy, Combination, Humans, Pyrazoles, Sulfonamides, Randomized Controlled Trials as Topic, Cyclooxygenase 2 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
